Table 2.
Characteristics of the patients in the simulated dataset
|
|
Other mode of action | TNF inhibitor |
| N | 1295 | 8705 |
| Disease duration (median (IQR) in year) | 9.7 (4.5, 17.8) | 7.3 (2.9, 14.3) |
| Treatment duration (median (IQR) in year) | 1.2 (0.5, 2.7) | 1.6 (0.5, 4.2) |
| Number of previous bDMARD (number (%)) | ||
| 0 | 326 (25.2) | 4973 (57.1) |
| 1 | 409 (31.6) | 2618 (30.1) |
| 2 | 294 (22.7) | 775 (8.9) |
| 3+ | 266 (20.5) | 339 (3.9) |
| Concomitant csDMARD (number (%)) | ||
| MTX | 611 (47.2) | 4330 (49.7) |
| MTX +other | 18 (1.4) | 248 (2.8) |
| None | 427 (33.0) | 3143 (36.1) |
| Other | 239 (18.5) | 984 (11.3) |
| CDAI0 (median (IQR)) | 23.2 (16.4, 32.4) | 23.0 (14.0, 33.3) |
| CDAI12 (median (IQR)) | 10.2 (5.3, 17.0) | 8.0 (3.4, 15.1) |
| treatment status (number (%)) | ||
| Ongoing | 740 (57.1) | 5355 (61.5) |
| Stopped for adverse event | 95 (7.3) | 407 (4.7) |
| Stopped for ineffectiveness | 159 (12.3) | 755 (8.7) |
| Stopped for pregnancy | 1 (0.1) | 11 (0.1) |
| Stopped for remission | 17 (1.3) | 41 (0.5) |
| Stopped for other | 57 (4.4) | 215 (2.5) |
| Stopped for unspecified reason | 226 (17.5) | 1921 (22.1) |
| LDA | 639 (49.3) | 5210 (59.9) |
Number of observations (N), number and proportion of patients having 0, 1, 2, 3 and more (3+) previous biological DMARD, of patient having methotrexate alone (MTX), methotrexate with other csDMARD (MTX +other), at least an csDMARD other than MTX (other) or no concomitant synthetic DMARD treatment (none), median (IQR) value of age, body mass index (BMI), baseline CDAI (CDAI0) and CDAI at 12 months (CDAI12).
CDAI, Clinical Disease Activity Index; csDMARD, conventional synthetic disease-modifying antirheumatic drugs; LDA, low disease activity; TNF, tumour necrosis factor.